Tag: chimeric antigen receptor
TGA OKs Novartis CAR-T cell therapy manufacturing in Melbourne
With TGA approval in check, Melbourne will house Australia's first and only commercial manufacturing site for the promising cancer treatment.
Swiss pharmaceutical company Novartis announced...
Featured Article
Navigating energy price volatility with predictive intelligence
Energy price volatility has become a structural feature of modern electricity markets rather than a temporary disruption. For energy-intensive manufacturers and large commercial operators, fluctuating wholesale prices are reshaping how energy costs are managed, making reactive approaches increasingly inadequate.
